Core Viewpoint - Progyny, Inc. anticipates that its fourth quarter and full year results for 2024 will be slightly above previously provided financial guidance, driven by improved member activity and treatment volume [1][3]. Financial Guidance - In November, the company had projected that member activity for the fourth quarter would be flat to down compared to the third quarter [2]. - As the fourth quarter progressed, the company observed favorable pacing in member activity, leading to an expectation of revenue, net income, and Adjusted EBITDA results exceeding prior guidance [3]. Conference Participation - Progyny will present at the 43rd Annual JP Morgan Healthcare Conference on January 14, 2025, where the CEO will discuss updated expectations for the company's performance [4]. Company Overview - Progyny is recognized as a transformative solution in fertility, family building, and women's health benefits, serving leading employers and health plans [6]. - The company emphasizes comprehensive and inclusive solutions that benefit employers, patients, and physicians [6][7]. Recognition and Awards - Progyny has received multiple accolades, including being named a TIME100 Most Influential Company and a CNBC Disruptor 50, highlighting its leadership and growth in the industry [8].

Core Viewpoint - Kuehn Law, PLLC is investigating potential breaches of fiduciary duties by certain officers and directors of Progyny, Inc. related to self-dealing, which may entitle shareholders to damages and corporate governance reforms [1]. Group 1 - The investigation focuses on whether the actions of Progyny's officers and directors constitute self-dealing [1]. - Shareholders may have the right to seek damages and advocate for changes in corporate governance as a result of the investigation [1]. Group 2 - Long-term shareholders of Progyny are encouraged to contact Kuehn Law for a free consultation regarding their rights [2]. - Kuehn Law covers all case costs and does not charge its investor clients, emphasizing the importance of timely action for shareholders [2]. Group 3 - The firm highlights the significance of shareholder participation in maintaining the integrity and fairness of financial markets [3]. - Kuehn Law promotes the idea that every shareholder's voice contributes to their investment future [3].

Paul Franke's Background and Investment Approach - Paul Franke is a private investor and speculator with 38 years of trading experience, known for his contrarian stock selection style and algorithm-based analysis of fundamental and technical data [1] - He developed the "Victory Formation" system, which identifies supply/demand imbalances through specific stock price and volume movements, and suggests using 10% or 20% stop-loss levels on individual choices [1] - Franke recommends a diversified approach of owning at least 50 well-positioned stocks to achieve regular stock market outperformance [1] - His "Bottom Fishing Club" articles focus on deep-value candidates or stocks experiencing a major reversal in technical momentum to the upside, while "Volume Breakout Report" articles discuss positive trend changes backed by strong price and volume trading action [1] Paul Franke's Achievements and Rankings - Franke was consistently ranked among top investment advisors nationally for stock market and commodity macro views by Timer Digest during the 1990s [1] - He was ranked 1 in the Motley Fool CAPS stock picking contest during parts of 2008 and 2009, out of 60,000+ portfolios [1] - As of September 2024, Franke was ranked in the Top 3% of bloggers by TipRanks for 12-month stock picking performance on suggestions made over the last decade [1] Paul Franke's Professional Experience - Franke was Editor and Publisher of the Maverick Investor newsletter during the 1990s, widely quoted by CNBC, Barron's, the Washington Post, and Investor's Business Daily [1] - He served as Director of Research at Quantemonics Investing from 2010-13, running several model portfolios on the Covestor.com mirror platform, including the least volatile, lowest beta, fully-invested equity portfolio on the site [1]

SAN DIEGO, Dec. 18, 2024 /PRNewswire/ -- Shareholder rights law firm Robbins LLP is investigating Progyny, Inc. (NASDAQ: PGNY) to determine whether certain Progyny officers and directors violated securities laws and breached fiduciary duties to shareholders. Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States.What Now: If you own shares of Progyny, Inc. and have lost money in your investment, contact us for more inf ...

Core Viewpoint - Robbins LLP is investigating Progyny, Inc. for potential violations of securities laws and breaches of fiduciary duties by certain officers and directors [1] Company Overview - Progyny, Inc. is a benefits management company that specializes in fertility and family building benefits solutions for employers in the United States [1] Legal Context - Shareholders who have lost money in their investment in Progyny, Inc. are encouraged to contact Robbins LLP for more information about their rights [2] - Robbins LLP operates on a contingency fee basis, meaning shareholders pay no fees or expenses unless a recovery is made [3] Firm Background - Robbins LLP has been dedicated to helping shareholders recover losses and improve corporate governance since 2002, having obtained over $1 billion for shareholders [4]

I recommended a buy rating for Progyny, Inc. (NASDAQ: PGNY ) when I wrote about it on 3rd June this year, as I saw no change to the long-term growth outlook and that anyI consider an investment ideal if it performs its core business in a sector projected to experience structural (organic) growth in excess of GDP growth over the next 5-10 years; profits from sustainable competitive advantages that translate into attractive unit economics; In the hands of competent, ethical, and long-term thinkers; with a fai ...

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or ...

NEW YORK, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a transformative fertility, family building, and women’s health benefits solution, today announced that Pete Anevski, Progyny’s Chief Executive Officer, and Mark Livingston, Chief Financial Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 8:00 a.m. GMT (3:00 a.m. EST). A live audiocast and replay will be available from the Events and Presentations section of P ...

Core Insights - Progyny's shares fell by 19% following disappointing Q3 results, missing analysts' expectations for revenue growth [1][2] - The company reported only 2% growth in Q3 and projected a mere 1.5% growth for Q4, leading to lowered price targets from Wall Street experts [2] - Despite a 19% increase in member count to 6.4 million, lower utilization rates contributed to the revenue shortfall, a situation not previously encountered by the company [3] Financial Performance - Progyny's revenue growth has significantly slowed from triple digits in 2020 to nearly flat today, with a notable decline attributed to the loss of a major customer, likely Amazon, which impacted growth by 1.4 percentage points [4] - The company's shares have decreased by 79% from their all-time highs, reflecting market concerns over its growth trajectory [4] Market Position - Progyny remains a leader in the fertility benefits sector, with increasing relevance as CDC data indicates that 1 in 5 couples in the U.S. face infertility issues, up from 1 in 8 in 2019 [5] - The stock is currently trading at 22 times this year's earnings and 9 times next year's, suggesting potential value for investors if the company can stabilize growth and utilization rates [6]

Group 1: Earnings Performance - Progyny reported quarterly earnings of $0.40 per share, exceeding the Zacks Consensus Estimate of $0.37 per share, and up from $0.16 per share a year ago, representing an earnings surprise of 8.11% [1] - The company has surpassed consensus EPS estimates for the last four quarters [2] - Progyny's revenues for the quarter ended September 2024 were $286.63 million, missing the Zacks Consensus Estimate by 2.78%, compared to $280.89 million in the same quarter last year [2] Group 2: Stock Performance and Outlook - Progyny shares have declined approximately 54.1% since the beginning of the year, while the S&P 500 has gained 25.8% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters [4] - The current consensus EPS estimate for the next quarter is $0.39 on revenues of $290.81 million, and for the current fiscal year, it is $1.56 on revenues of $1.17 billion [7] Group 3: Industry Context - The Medical Services industry, to which Progyny belongs, is currently ranked in the bottom 45% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Progyny's stock performance [5][6]